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Abstract 
Background: Pheochromocytoma, a rare catecholamine‑producing tumor, might provoke stress‑induced Takot‑
subo‑like cardiomyopathy and severe cardiogenic shock. Because venoarterial‑extracorporeal membrane oxygena‑
tion (VA‑ECMO) rescue of pheochromocytoma‑induced refractory cardiogenic shock has rarely been reported, we 
reviewed our ICU patients’ presentations and outcomes.
Methods: All pheochromocytoma‑induced refractory cardiogenic shock cases managed with VA‑ECMO (January 
2007–March 2015) were prospectively included and reviewed. We also performed a systematic review on this topic.
Results: Nine patients (7 women, 2 men; 31–51 [median, 43 (IQR 36–49) years old]) were included; none had a previ‑
ously known pheochromocytoma. Six of them had medical histories suggestive of the diagnosis: palpitations and 
headaches for several months for four, multiple endocrine neoplasia syndrome type 1 for one and recurrent Takotsubo 
disease for one; at hospital admission, all were hypertensive despite cardiogenic shock. Three others had an identified 
surgical triggering factor. All nine patients rapidly developed refractory cardiogenic shock with very severe left ventricular 
(LV) impairment (LV ejection‑fraction range 5–20%; LV outflow‑tract velocity–time integral range 3–8 cm). Seven patients’ 
abdominal computed tomography scans showed pheochromocytoma‑suggestive adrenal gland tumors (no scan dur‑
ing ICU stay for 2). Despite VA‑ECMO implantation, three patients died of refractory multiple organ failure. For the six oth‑
ers, myocardial function improved and ECMO was removed 3–7 days post‑implantation; α‑ and β‑blockers were progres‑
sively introduced. Five survivors underwent pheochromocytoma excision 3 weeks–4 months post‑ICU discharge, with 
satisfactory outcomes. One patient, whose pheochromocytoma was diagnosed 1 year after the index event, underwent 
uneventful surgical adrenalectomy. Systematic review retrieved 40 cases of pheochromocytoma‑induced cardiogenic 
shock requiring mechanical support (mostly ECMO), with a mortality rate of 7%. Pheochromocytoma was removed surgi‑
cally after mechanical support weaning in 31 patients and during mechanical support in 5. Four were not operated.
Conclusions: Pheochromocytoma is a rare but reversible cause of cardiogenic shock amenable to VA‑ECMO rescue. 
Adrenal gland imaging should be obtained for all patients with unexplained cardiogenic shock. Lastly, it might be 
safer to perform adrenalectomy several weeks after the initial catastrophic presentation, once recovery of LV systolic 
function is complete.
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Background
Pheochromocytoma, called paraganglioma when extra-
adrenal, is a rare catecholamine-secreting neuroendo-
crine tumor arising from chromaffin cells in the adrenal 
medulla. Its usual clinical picture combines persistent 
or paroxysmal hypertension, palpitations, headache, 
diaphoresis, tremors and/or anxiety. However, life-
threatening complications, such as Takotsubo-like car-
diomyopathy and cardiogenic shock, have been described 
and are often fatal. In this setting, venoarterial-extra-
corporeal membrane oxygenation (VA-ECMO) might 
be the only way to prevent death, but only a few cases of 
ECMO-managed pheochromocytoma-induced cardio-
genic shock have been published.
Methods
We  reviewed the presentations and outcomes of nine 
patients admitted to our ICU for pheochromocytoma-
induced refractory cardiogenic shock rescued by VA-
ECMO between January 2007 and March 2015 (Table 1). 
For our literature review, the MEDLINE database was 
searched using “pheochromocytoma” and “cardio-
genic shock” as key words. Articles were screened and 
those reporting cardiogenic shock requiring mechanical 





A 41-year-old man consulted the emergency department 
(ED) for acute abdominal pain with nausea and vomit-
ing. He had a 1-year history of hypertension and stated 
having had palpitations and headaches for several years. 
At admission, his blood pressure was 160/120  mmHg; 
physical examination and chest X-ray were consistent 
with severe pulmonary edema. His electrocardiogram 
indicated sinus tachycardia and ST-segment elevation 
in leads V1–V3. Transthoracic echocardiography (TTE) 
showed very severe left myocardial impairment with left 
ventricular ejection fraction (LVEF) at 5%. Dobutamine 
then epinephrine infusion obtained no improvement. 
Under VA-ECMO implanted before he was transferred to 
our ICU, he rapidly recovered cardiac function, allowing 
ECMO weaning on day 4. Post-weaning, he developed 
severe hypertension that required nicardipine infusion. 
Abdominal ultrasonography visualized a 7-cm-diameter 
lesion in the right adrenal gland, confirmed by computed 
Table 1 Clinical and biological characteristics of the nine patients
ECMO extracorporeal membrane oxygenation, LVEF left ventricle ejection fraction, N normal value, ND not done
Characteristic Case 1 Case 2 Case 3 Case 4 Case 5 Case 6 Case 7 Case 8 Case 9
Sex Male Female Female Female Female Female Female Male Female





Yes Yes Yes Yes







160/120 180/108 157/107 130/110 140/100 130/85 141/107 160/100 129/99
Pre‑ECMO LVEF (%) 5 20 15 20 30 20 20 30 20
Maximum troponin 
I (ng/L)
2200 34,000 43,000 15,000 2000 18,000 237 4994 2083
NT pro‑BNP at 
admission (ng/L)
18,363 25,282 6363 18,471 9264
ECMO duration 
(days)
4 1 6 7 3 3 2 7 4
Urinary 
metanephrine 
(N < 340 µg/24 h)
ND ND ND ND 1894 7192 8738 2862 2582
Urinary norme‑
tanephrine 
(N < 440 µg/24 h)
ND ND ND ND 4973 3650 11,910 11,268 9254
Pheochromocytoma 
size (mm), side
78 × 75 × 70, 
right
60 mm, left ND, autopsy 29, left 70, left 103 × 95 × 75, 
right
57 × 47, 
right
59 × 38, left 88 × 74×91, 
left
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tomography (CT). Four days after ECMO weaning, while 
under nicardipine infusion, labetalol and ramipril, he 
developed malignant hypertension (blood pressure at 
270/120  mmHg) and cardiogenic shock complicated by 
cardiac arrest. VA-ECMO was re-implanted, but he died 
of refractory multiorgan failure. Autopsy confirmed the 
pheochromocytoma diagnosis.
Case 2
A 44-year-old woman underwent elective hysteroscopic 
resection of a bleeding uterine fibroid. Her medical his-
tory included migraines, sweating episodes, appendicu-
lar peritonitis in childhood and uterine fibroids. While 
in the recovery room, she became hypertensive (blood 
pressure 180/108  mmHg) and polypneic, with clinically 
and radiographically diagnosed pulmonary edema. TTE-
estimated LVEF was 20%. Despite nitrates and diuretics, 
her clinical status abruptly deteriorated with cardiogenic 
shock, renal and hepatic failures, and hyperlactatemia 
(9 mmol/L). She was intubated, epinephrine infusion was 
started and progressively increased to 4  mg/h, and our 
ECMO mobile team implanted VA-ECMO. Post-implan-
tation, her severe hypertension (mean blood pressure at 
150 mmHg) required antihypertensive therapy. Abdomi-
nal CT revealed a 6-cm tumor in the right adrenal gland. 
Her hemodynamic status worsened under VA-ECMO 
with major capillary leak syndrome requiring vascular 
filling; she died several hours later.
Case 3
After 1  week of ineffective antibiotics, a 36-year-old 
woman was referred to her local ED for persistent febrile 
headaches, cough and vomiting. Her history consisted 
of type 1 neurofibromatosis, headaches and palpitations. 
At admission, her blood pressure was 157/107  mmHg 
and her heart rate 162  beats/min. Suddenly, she devel-
oped massive pulmonary edema with cardiogenic shock 
requiring mechanical ventilation and dobutamine infu-
sion. TTE revealed severe global hypokinesia with LVEF 
at 20%. She developed multiorgan failure, and our ECMO 
mobile team implanted VA-ECMO. On day 4, she suf-
fered a massive ischemic stroke, cerebral herniation and 
cerebral death. During her stay, abdominal ultrasonogra-
phy found a left adrenal tumor; autopsy confirmed a left 
adrenal pheochromocytoma.
Case 4
After 2 weeks of antibiotics and corticosteroids for bron-
chitis, a 45-year-old woman went to her local ED for 
acute chest pain. She had no remarkable medical history. 
At admission, BP was 130/110 mmHg, her heart rate was 
86 beats/min, and oxygen saturation was 98% breathing 
ambient air. She rapidly developed signs of respiratory 
and hemodynamic failure, and mechanical ventilation 
was started. Her electrocardiogram indicated sinus tach-
ycardia and ST-segment elevation in leads V2–V3. 
TTE revealed severe LV dysfunction with LVEF at 20%. 
Refractory electrical storm ensued, requiring VA-ECMO 
implantation by the ECMO mobile team after 45 min of 
cardiopulmonary resuscitation. Peripheral ECMO was 
switched to central ECMO during her ICU stay. Car-
diac biopsies taken during the switch contained fibrosis 
and lymphocytic infiltration without necrosis, sugges-
tive of borderline myocarditis. Heart function recovered 
and ECMO was removed 7 days post-implantation. After 
5 weeks in ICU complicated by ischemic stroke, she was 
discharged from the hospital. Several months later, a 
CT scan for abdominal pain visualized an adrenal mass, 
whose radiologic appearance suggested pheochromocy-
toma. She underwent laparoscopic adrenalectomy under 
stable hemodynamic conditions; histologic examination 
of the mass confirmed the pheochromocytoma diagnosis.
Case 5
A 43-year-old woman went to her ED for acute chest 
pain, palpitations, dyspnea and vomiting a few hours 
after dental care. She had been hospitalized 8  months 
earlier for acute coronary syndrome with normal coro-
nary angiography after mammoplasty, and 4 months ago 
for Takotsubo syndrome following dental care. At admis-
sion, her BP was 140/100 mmHg and pulse rate 97/min. 
Acute respiratory distress required immediate mechani-
cal ventilation. Her electrocardiogram revealed nega-
tive T waves on lateral leads. Troponin I was at 2 µg/L. 
TTE found severe LV systolic dysfunction (LVEF at 20%), 
with apical ballooning. Despite infused dobutamine and 
epinephrine (gradually increased to 15  mg/h), circula-
tory failure worsened and femoral–femoral VA-ECMO 
was implanted. Within few hours, the patient’s hemo-
dynamics improved and, after discontinuing catechola-
mine infusion, a hypertensive crisis occurred. Abdominal 
ultrasonography discovered a 7-cm left adrenal lesion 
confirmed by CT. ECMO was removed on day 3 with 
full recovery of heart systolic function; α- and β-blockers 
(prazosin and atenolol) were started. Six weeks after 
admission, she underwent uncomplicated adrenalec-
tomy; histologic examination of the mass confirmed the 
pheochromocytoma diagnosis.
Case 6
A 51-year-old woman, with no remarkable medical his-
tory, underwent elective abdominal hernia repair. During 
surgery, she developed hypertensive cardiogenic pulmo-
nary edema. TTE revealed Takotsubo cardiomyopathy, 
with LV apical akinesis and LVEF at 25%. Her electro-
cardiogram indicated ST-segment depression on lateral 
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leads. Inotropic support was ineffective, and VA-ECMO 
was implanted. Abdominal CT showed a 10-cm-diameter 
lesion in the right adrenal gland with central necrosis. 
Elevated urinary metanephrine and normetanephrine, 
and scintigraphy with metaiodobenzylguanidine con-
firmed the pheochromocytoma diagnosis. Prazosin 
(α-blocker) was initiated, and she was weaned off ECMO 
on day 3. During hospitalization, she developed numer-
ous hypertensive crises that were controlled medically. 
The lesion/mass was successfully excised 6  weeks post-
admission. Histology of the surgical specimen confirmed 
necrotic pheochromocytoma. The patient was well at 
3-year follow-up.
Case 7
A 49-year-old woman, with no remarkable medical his-
tory, had fever, cough and myalgia of 2-week duration. 
She was referred to the ED for acute dyspnea and cir-
culatory failure. At admission, her blood pressure was 
120/100  mmHg, pulse 137/min and severe cardiogenic 
pulmonary edema required rapid intubation. TTE-meas-
ured LVEF was at 20%. Antibiotics and oseltamivir were 
started for suspected fulminant myocarditis. Despite 
maximal inotropic support, adequate perfusion could 
not be achieved and femoral–femoral VA-ECMO was 
implanted, complicated a few hours later by acute right 
inferior limb ischemia with compartment syndrome. 
On day 2, partial hemodynamic improvement allowed 
ECMO removal and right limb aponeurotomy. Abdomi-
nal ultrasonography visualized a large right adrenal mass. 
LV systolic function recovered fully. Antihypertensive 
medications (prazosin and β-blockers) were started. 
Right adrenalectomy was performed 6 weeks later; histo-
logic examination of the mass confirmed the pheochro-
mocytoma diagnosis.
Case 8
A 31-year-old man consulted his local ED for palpita-
tions, and headaches associated with chest and abdomi-
nal pain. During the preceding year, he had experienced 
episodic headaches, sweating and palpitations. At physi-
cal examination BP was 160/100  mmHg, pulse 160/
min, temperature 38.5  °C. His electrocardiogram indi-
cated ST-segment depression in inferior–lateral leads, 
and troponin I was at 4994  ng/L. Emergency coronary 
artery angiography was normal. His respiratory and 
hemodynamic status worsened, necessitating mechani-
cal ventilation and hemodynamic support. TTE showed 
severe LV hypokinesia with LVEF at 30%. VA-ECMO was 
implanted for refractory cardiogenic shock. Abdominal 
CT discovered a 5-cm left adrenal mass. Prazosin was 
started and controlled hemodynamic variations. ECMO 
was removed 7  days post-implantation. The patient 
underwent surgery 6  weeks later and was discharged in 
good condition.
Case 9
Two days after the onset of flu-like symptoms, a 47-year-
old woman with a history of morbid obesity and depres-
sion went to the ED for abdominal pain, vomiting and 
myalgia. Physical examination found temperature at 
38.4  °C, BP 129/99  mmHg, pulse 138/min, respiratory 
rate 24/min and initial oxygen saturation 97% breathing 
ambient air, but the rapid deterioration of her respiratory 
and hemodynamic status required oxygen therapy and 
mechanical ventilation. Her echocardiography revealed 
severe LV dysfunction, with apical thrombosis. Tro-
ponin I was at 2083 ng/L. Despite inotropic support, her 
hemodynamics worsened and VA-ECMO was implanted. 
Hemodynamics quickly improved, and ECMO was 
removed on day 4. She suffered an embolic stroke that 
caused left hemiplegia. Abdominal CT showed a mul-
tinodular formation near the left adrenal gland, whose 
enhancement and density were compatible with a para-
ganglioma. She was started on α- and β-blockers and dis-
charged to a neurologic rehabilitation center. Her tumor 
was excised 4 months later; histology confirmed a volu-
minous paraganglioma.
Literature review
We conducted a systematic MEDLINE database litera-
ture review through the PubMed search engine, between 
2000 and 2016, using the following criteria: pheochro-
mocytoma and cardiogenic shock, pheochromocytoma 
and ECMO, pheochromocytoma and mechanical circu-
latory support, Takotsubo and cardiogenic shock, adr-
energic cardiomyopathy and cardiogenic shock. We also 
searched the references of identified studies. Observa-
tional studies and case series reporting on adult patients 
having required mechanical circulatory support for phe-
ochromocytoma-induced cardiogenic shock were eligi-
ble. Studies on children or newborns, those without any 
outcome information, were excluded.
Two authors (G.H. and N.B.) independently reviewed 
the retrieved abstracts and assessed eligibility. A third 
author (C.E.L.) determined eligibility in the case of 
disagreement.
The following data were extracted: study design, par-
ticipants’ characteristics (including echocardiographic 
data), type of mechanical circulatory support, outcome 
data (hospital mortality).
Forty cases of patients suffering from pheochromocy-
toma-induced cardiogenic shock requiring mechanical 
circulatory support (except use of intra-aortic balloon 
pump alone) were reported in the literature (Table  2). 
Twenty (50%) were women, and their median age was 
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Table 2 Case reports of pheochromocytoma-induced cardiogenic shock requiring mechanical circulatory support















Takagi [17] 2000 1 52 M 9 ECMO and IABP; 3 NR, after ECMO 
weaning
Yes
Grinda [18] 2006 1 49 M 12 ECMO, then LVAD; 4, 
then 70, respectively
4 Yes
Ouchikhe [19] 2006 1 23 M 20 ECMO, then Thoratec 
BiVAD; 84
93 Yes
Kim [20] 2007 1 47 M 23 ECMO and IABP; 10 15 Yes
Chao [21] 2008 1 42 M 20 ECMO and IABP; 7 18 Yes
Zegdi [22] 2008 1 51 F 30 ECMO; 6 30 Yes
Huang [23] 2008 3 25 F NR ECMO and IABP; 4 NR, after ECMO 
weaning
Yes
42 M NR ECMO and IABP; 7 NR, after ECMO 
weaning
Yes
41 F <NR ECMO and IABP; 2 NR, after ECMO 
weaning
Yes
Grasselli [24] 2008 1 47 F 30 ECMO; 4 7 Yes
Suh [25] 2008 1 43 M 27 ECMO and IABP; 4 56 Yes
Wu [26] 2008 2 42 M 34 ECMO and IABP; 8 21 Yes
40 M 30 ECMO and IABP; 4 12 Yes




Park [28] 2009 1 41 M 20 ECMO and IABP; 2 30 Yes
Westaby [12] 2009 1 27 M 15 CBP and adrenalectomy, 
then LVAD; 6
1 Yes
Raikhelkar [29] 2010 1 38 M 5 Thoratec BiVAD; 4 24 Yes
Xeridat [25] 2011 1 16 F 20 ECMO; 6 21 Yes
Ritter [30] 2011 1 49 F 10 ECMO; 8 8 Yes
Nakajima [31] 2011 1 33 F 19 ECMO and IABP; 4 120 Yes
Contargyris [32] 2012 1 20 M 20 ECMO; 2 30 Yes
Sojod [33] 2012 1 37 F 15 ECMO; 11 21 Yes
Sheinberg [34] 2012 1 45 F 5 ECMO and IABP; 3 56 No
Noorani [35] 2012 1 39 F NR Central ECMO; 5 3 Yes
Banfi [36] 2012 1 20 F 20 Central ECMO; 6 120 Yes
Kaese [37] 2013 1 43 M NR ECMO; 9 NR, after ECMO 
weaning
Yes
Law [38] 2013 1 23 F 5 ECMO; 1 NR, after ECMO 
weaning
Yes
Shawa [39] 2014 1 38 F 15 Tandem Heart; 1 26 Yes
Riester [1] 2015 2 18 F NR Impella; 2 No surgery No
25 F NR ECMO; NR NR, after ECMO 
weaning
Yes
Chao [2] 2015 4, 2 with IABPa 25 F NR ECMOa NR, after ECMO 
weaning
Yes
52 M NR ECMOa NR, after ECMO 
weaning
Yes
40 M NR ECMOa NR, after ECMO 
weaning
Yes
65 M NR ECMOa Refused surgery Yes
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40  years (IQR 31–49  years). Left ventricular dysfunc-
tion was very severe in all cases with a median LVEF of 
15% (IQR 10–20%). ECMO was used in 35 patients, 2 
patients had Impella device, 1 had Tandem Heart device, 
2 had cardiopulmonary bypass to facilitate pheochromo-
cytoma surgery, and 4 patients had long-term mechani-
cal circulatory support. Median duration of mechanical 
circulatory support was 4 days (IQR 1.5–6.5 days). Pheo-
chromocytoma was removed surgically after mechanical 
circulatory support weaning in 29 patients and while on 
mechanical circulatory support in 7. Two patients died 
before surgery, one patient declined, and the timing of 
surgery was not reported in the last case. The median 
ICU-admission-to-surgery interval was 23  days (IQR 
1–46 days). Thirty-seven of the 40 (93%) reported cases 
survived.
Discussion
We described nine critical presentations of undiagnosed 
pheochromocytoma with refractory cardiogenic shock 
requiring VA-ECMO salvage therapy.
Many cardiac manifestations of pheochromocytoma 
have been reported, including Takotsubo-like cardiomy-
opathy, myocardial infarction, pulmonary edema and/or 
hypertensive crisis [1], but only rarely inaugural refrac-
tory cardiogenic shock requiring VA-ECMO (Table  2). 
This is, to our knowledge, the largest case series of phe-
ochromocytoma-induced refractory cardiogenic shock. 
As previously reported [1, 2], the major clinical feature 
was the sequence of initial hypertensive crisis followed by 
hypotensive shock, probably caused by severe LV failure. 
Following ECMO implantation, all our patients suffered 
paroxysmal hypertension with wide and rapid blood 
pressure fluctuations.
Coronary angiography should be considered in every 
patient with unexplained cardiogenic shock, especially 
in cases of ST-segment deviation. It was performed in 
patient 8, and patient 5 had a normal coronary catheteri-
zation a few months ago. In our study, the other patients 
did not have this examination because three had a clini-
cal presentation highly suggestive of myocarditis and 
four had clinical characteristics suggestive of pheochro-
mocytoma with early diagnosis performed on abdominal 
imaging.
Cardiogenic shock is a rare but potentially lethal pheo-
chromocytoma manifestation, and in our series, three of 
the nine patients died. For the six survivors, mechanical 
circulatory support was probably the only way to prevent 
death. Because ECMO allows quick and easy percutane-
ous insertion of cannulae, full circulatory support and 
improved tissue oxygenation in situations of cardiogenic 
shock combined with severe pulmonary edema [3, 4], it 
was preferred over other assisted support options for all 
these patients. Pertinently, cardiac dysfunction reversibil-
ity in these pheochromocytoma-induced cardiomyopa-
thies is well established; all six survivors were all weaned 
off ECMO within a week and recovered normal myocar-
dial systolic function.
Catecholamine-mediated cardiomyopathy is not com-
pletely understood. Proposed mechanisms include coro-
nary artery or microvascular spasms leading to focal 
myocardial necrosis [5], direct cellular toxicity through 
increased intracellular calcium concentrations [6] or 
damage induced by reactive oxygen species [7], and myo-
cardial stunning due to receptor desensitization and/
or downregulation [8]. When obtained, endomyocardial 
biopsies contained nonspecific contraction band necrosis 
[9]. Our patient 4’s suspected myocarditis biopsy con-
tained lymphocytic infiltration and focal fibrosis, without 
necrosis.
In reported cases [10] and our experience, once the ini-
tial critical context has been controlled, heart failure is 
fully reversible within a few days, suggesting stunning or 
metabolic anomaly rather than myocardial necrosis.
Table 2 continued















Flam [10] 2015 1 46 F 15 ECMO; 5 66 Yes
Vagner [41] 2015 1 55 F 15 Impella, then ECLS; 2 56 Yes
Spangenberg [14] 2015 1 29 F 10 ECMO and IABP; 1 No surgery No
Kodama [9] 2016 1 37 F 10 ECMO; NR NR, before ECMO 
weaning
Yes
Dang Van [42] 2016 1 57 M 10 ECMO, 7 NR, concomitant 
from the ECMO 
implantation
Yes
IABP intra-aortic balloon pump, NR not reported, CPB cardiopulmonary bypass, LVAD left ventricular assist device, BiVAD biventricular assist device, ECLS extracorporeal 
life support
a Chao et al. did not specify which two patients had ECMO and IABP and individual ECMO durations were not given
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Medical management of pheochromocytoma-induced 
cardiogenic shock raises some concerns. Various drugs, 
including adrenaline, noradrenaline, dobutamine, vaso-
pressin and levosimendan, were used in case reports. 
Because exposure to elevated epinephrine levels may 
engender cardiac dysfunction and sympathetic recep-
tor downregulation, catecholamines usually used to treat 
cardiogenic shock could be less effective or even exac-
erbate pheochromocytoma-induced cardiogenic shock. 
Some authors proposed alternative agents that do not 
act via adrenergic receptors, such as calcium-sensitizing 
agents or phosphodiesterase III inhibitors, but no avail-
able evidence supports those decisions [11, 12].
Cardiogenic shock was the first main manifesta-
tion of undiagnosed pheochromocytoma for most of 
our patients, but some clinical manifestations could 
help guide the diagnosis. The major characteristic was 
hypertension at admission contrasting with evidence of 
circulatory failure. Symptoms suggestive of pheochromo-
cytoma, e.g., headaches, sweating and palpitations, were 
retrospectively found in four patients, one had type 1 
neurofibromatosis, and one had experienced two Takot-
subo cardiomyopathy episodes. During recovery, four of 
them developed severe paroxysmal hypertension, also 
evocative of pheochromocytoma.
Precipitating circumstances were identified for some 
patients. Three relatively asymptomatic patients’ previ-
ously undiagnosed pheochromocytomas were unmasked 
by elective surgery, manifesting as peri- or postopera-
tive hypertensive crises and subsequent  cardiogenic 
shock. Johnston et al. described two similar patients with 
hypertensive crises and cardiogenic shock unmasked 
by elective surgical procedures [11]. In such periopera-
tive situations, acute intra-tumor hemorrhagic necrosis 
may precipitate catecholamine release, thereby induc-
ing acute cardiogenic shock. Four patients had flu-like 
symptoms (fever, cough, myalgia) and acute heart failure 
with LV dysfunction and pulmonary edema, suggestive of 
myocarditis [13]. This particular clinical picture of pheo-
chromocytoma mimicking fulminant myocarditis has 
been described previously [14] and should be known to 
physicians.
For our patients, pheochromocytoma was diagnosed 
based on abdominal CT or ultrasonography and then 
confirmed by elevated urinary catecholamines. Pheo-
chromocytoma diagnosis usually relies on measuring 
plasma or urine metanephrines. However, cardiogenic 
shock and hypertensive crisis can physiologically increase 
catecholamine release and these patients frequently 
receive adrenaline or noradrenaline infusions. For those 
two reasons, metanephrine levels cannot be used in this 
setting to diagnose pheochromocytoma. As Amar and 
Eisenhofer suggested, this situation requires immediate 
imaging studies to search for a pheochromocytoma with-
out prior biochemical evidence of a catecholamine-pro-
ducing tumor [15].
A difficult issue is the optimal timing of pheochromo-
cytoma excision. In a recent retrospective cohort study 
and literature review, emergency surgery during hyper-
tensive crisis was associated with higher mortality and 
morbidity [16]. Stabilization with α-blockade prior to 
elective surgery was associated with shorter hospital 
stays and fewer postoperative complications. It seems 
useful to minimize the risk of catecholamine-induced 
hemodynamic fluctuations during anesthesia or pre-abla-
tion tumor mobilization during surgery. Calcium channel 
blockers may be added, if necessary.
In our case series, α-blockers were gradually intro-
duced in hemodynamically stabilized patients, followed 
by β-blockers to prevent tachycardia once cardiac systolic 
function had recovered and ECMO had been removed.
Five survivors underwent adrenalectomy 3  weeks to 
4  months after the initial emergency presentation; the 
sixth pheochromocytoma was diagnosed 1  year later 
and removed under stable conditions and without peri-
operative complications. Celioscopic adrenalectomy 
was achievable in the six patients once heart function 
had fully recovered. None of these patients experienced 
another severe hypertensive crisis on α- and β-blockers 
before surgery. All six have been asymptomatic since the 
intervention.
As compared to previously reported cases, we 
described nine consecutive patients whereas most 
reported cases were single cases. Our patients were glob-
ally similar to previously reported cases: They shared 
same clinical characteristics and same short duration of 
ECMO support, and most adrenalectomy procedures 
were delayed after myocardial recovery. Contrasting with 
the good outcome (37/40 patients survived) of the previ-
ously reported patients, three of our nine patients died. 
This could be explained by publication bias related to 
single case reports; authors report most often successes 
than failures. Clinicians should be aware of this rare but 
curable cause of cardiogenic shock; it can be suspected 
in patients with cardiogenic shock associated with hyper-
tension and easily confirmed using abdominal imaging. 
Moreover, we describe here a homogenous and suc-
cessful single-center strategy for pheochromocytoma-
induced cardiogenic shock management from the initial 
critical presentation to the scheduled adrenalectomy 
after heart recovery.
Conclusion
Pheochromocytoma should systematically be considered 
for patients with Takotsubo cardiomyopathy, myocardi-
tis, perioperative hypertensive crisis and/or unexplained 
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cardiogenic shock. The definitive diagnosis is based on 
characteristic clinical features and abdominal imag-
ing. For the most severe cases, ECMO support can be a 
life-saving therapy, allowing myocardial recovery within 
a few days. After hemodynamic stabilization, treatment 
should include α-blockade, with elective pheochromocy-
toma removal scheduled after myocardial recovery under 
stable conditions.
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